Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage the women's health. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons primarily in Australia and the United States. The company has research and services agreement with The University of Melbourne for the development and enhancement of the BREVAGenplus breast cancer risk assessment test. Genetic Technologies Limited was founded in 1989 and is headquartered in Fitzroy, Australia.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:GENE
CUSIPN/A
Phone61-3-8412-7000
Debt
Debt-to-Equity RatioN/A
Current Ratio7.02
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$390,000.00
Price / Sales44.56
Cash FlowN/A
Price / CashN/A
Book Value$0.49 per share
Price / Book2.18
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees20
Outstanding Shares16,240,000
Genetic Technologies (NASDAQ:GENE) Frequently Asked Questions
What is Genetic Technologies' stock symbol?
Genetic Technologies trades on the NASDAQ under the ticker symbol "GENE."
Who are some of Genetic Technologies' key competitors?
Some companies that are related to Genetic Technologies include Champions Oncology (CSBR), BioCardia (BCDA), TRACON Pharmaceuticals (TCON), Proteon Therapeutics (PRTO), BIONDVAX PHARMA/S (BVXV), CytRx (CYTR), Microbot Medical (MBOT), aTyr Pharma (LIFE), Oncobiologics (ONS), Vical (VICL), Vaxart (VXRT), Titan Pharmaceuticals, Inc. common stock (TTNP), Neuralstem (CUR), Windtree Therapeutics (WINT) and Mymetics (MYMX).
Who are Genetic Technologies' key executives?
Genetic Technologies' management team includes the folowing people:
- Dr. Paul Alexander Kasian Ph.D., Chairman & Acting CEO (Age 61)
- Mr. Kevin Fischer CPA, AGIA, ACIS, B.Com., CFO & Company Sec.
- Dr. Richard Allman Ph.D., Scientific Director (Age 58)
- Ms. Diana Newport, Quality & Bus. Operations Director (Age 61)
- Ms. Bronwyn M. Christie B.Com., CPA, Grd Dip C.G., Financial Controller
Has Genetic Technologies been receiving favorable news coverage?
Media stories about GENE stock have trended somewhat positive recently, according to Accern Sentiment. The research firm ranks the sentiment of press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Genetic Technologies earned a media sentiment score of 0.08 on Accern's scale. They also gave headlines about the biotechnology company an impact score of 44.59 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near future.
How do I buy shares of Genetic Technologies?
Shares of GENE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Genetic Technologies' stock price today?
One share of GENE stock can currently be purchased for approximately $1.07.
How big of a company is Genetic Technologies?
Genetic Technologies has a market capitalization of $17.37 million and generates $390,000.00 in revenue each year. Genetic Technologies employs 20 workers across the globe.
How can I contact Genetic Technologies?
Genetic Technologies' mailing address is 60-66 HANOVER STREET, FITZROY C3, 3065. The biotechnology company can be reached via phone at 61-3-8412-7000 or via email at [email protected]
MarketBeat Community Rating for Genetic Technologies (GENE)
MarketBeat's community ratings are surveys of what our community members think about Genetic Technologies and other stocks. Vote "Outperform" if you believe GENE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GENE will underperform the S&P 500 over the long term. You may vote once every thirty days.
